Cargando…

400 Exploring the Diversity of Expanded Access Patients at Michigan Medicine

OBJECTIVES/GOALS: Lack of diversity within clinical trials is well known, but there is little data on the use of investigational products through other pathways, such as expanded access. This project sought to determine the demographic diversity of patients benefiting from expanded access at Michiga...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gravelin, Misty, Frank, Chelsea, Rigan, Laurie, Wright, Jeanne, Weatherwax, Kevin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Cambridge University Press 2023
Materias:	Regulatory Science
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10129718/ http://dx.doi.org/10.1017/cts.2023.435

Ejemplares similares

2276 Development of the expanded access oversight committee at Michigan Medicine
por: Weatherwax, Kevin, et al.
Publicado: (2018)

National landscape assessment of academic medical center support for expanded access to investigational products
por: Gravelin, Misty, et al.
Publicado: (2022)

Adapting an Expanded Access program to enable investigational treatments for COVID-19
por: Samuels, Elias, et al.
Publicado: (2022)

Right now, in the right way: U. S. Food and Drug Administration’s expanded access program and patient rights
por: Holbein, M. E. Blair, et al.
Publicado: (2018)

Real-World Data Collection from Expanded Access Case Studies for the Treatment of Nontuberculous Mycobacterial Infection with Clofazimine
por: Gravelin, Misty, et al.
Publicado: (2023)

Role of CTSA institutes and academic medical centers in facilitating preapproval access to investigational agents and devices during the COVID-19 pandemic
por: Gravelin, Misty, et al.
Publicado: (2021)

2489 Perceptions of “translation” and the application of research across disciplines at the University of Michigan
por: Gravelin, Misty, et al.
Publicado: (2018)

Drug Lag and Key Regulatory Barriers in the Emerging Markets
por: Wileman, Harriet, et al.
Publicado: (2010)

Regulations and guidelines governing stem cell based products: Clinical considerations
por: George, Bobby
Publicado: (2011)

Regulatory Considerations for Biosimilars
por: Nellore, Ranjani
Publicado: (2010)

Registration of Medical Devices
por: George, Bobby
Publicado: (2010)

Implications of ICH-E5: Assessment of drug's sensitivity to ethnic factors and necessity of a bridging study for global drug development
por: Gupta, Sandeep Kumar
Publicado: (2011)

Regulatory requirements for marketing fixed dose combinations
por: Jayasheel, B. G.
Publicado: (2010)

Injury and death in clinical trials and compensation: Rule 122 DAB
por: Ghooi, Ravindra. B.
Publicado: (2013)

Key points of technical review for the registration of SARS-CoV-2 antigen/antibody tests
por: Li, Hongran, et al.
Publicado: (2021)

China NMPA perspective on clinical evaluation of SARS-CoV-2 antibody test reagents in the process of emergency approval
por: Lv, Yunfeng, et al.
Publicado: (2020)

Key points of technical review for the registration of SARS-CoV-2 nucleic acid tests in China
por: Li, Hongran, et al.
Publicado: (2021)

China's NMPA perspective on the clinical performance of SARS-CoV-2 antigen test reagents
por: Lv, Yunfeng, et al.
Publicado: (2022)

A new conceptional model for deriving average dermal absorption estimates from studies with multiple tested concentrations for non-dietary risk assessment of pesticides
por: Kluxen, Felix M., et al.
Publicado: (2022)

Recent progress to shorten premarket evaluation and improve patient access to medical devices by the Pharmaceuticals and Medical Devices Agency of Japan
por: Handa, Nobuhiro, et al.
Publicado: (2019)

Screening of chemicals for human bioaccumulative potential with a physiologically based toxicokinetic model
por: Tonnelier, Arnaud, et al.
Publicado: (2011)

Indian Regulatory Update: Jan-May 2014
por: Suvarnapathaki, Kedar
Publicado: (2014)

Sensory irritation as a basis for setting occupational exposure limits
por: Brüning, Thomas, et al.
Publicado: (2014)

Indian Regulatory Update: June-August 2014
por: Suvarnapathaki, Kedar
Publicado: (2014)

Indian regulatory update 2013
por: Suvarnapathaki, Kedar
Publicado: (2013)

Indian Regulatory Update: September-November 2013
por: Suvarnapathaki, Kedar
Publicado: (2014)

Indian Regulatory Update: January-March 2015
por: Suvarnapathaki, Kedar
Publicado: (2015)

Good Clinical Practice Training: Identifying Key Elements and Strategies for Increasing Training Efficiency
por: Arango, Jaime, et al.
Publicado: (2016)

Translating New Science Into the Drug Review Process: The US FDA’s Division of Applied Regulatory Science
por: Rouse, Rodney, et al.
Publicado: (2017)

Indian Regulatory Update: January-December 2017
por: Bhave, Amita
Publicado: (2018)

Standardisation of defined approaches for skin sensitisation testing to support regulatory use and international adoption: position of the International Cooperation on Alternative Test Methods
por: Casati, S., et al.
Publicado: (2017)

Predicting in vivo effect levels for repeat-dose systemic toxicity using chemical, biological, kinetic and study covariates
por: Truong, Lisa, et al.
Publicado: (2017)

Indian Regulatory Update: January – March 2018
por: Bhave, Amita
Publicado: (2018)

Current pesticide dietary risk assessment in light of comparable animal study NOAELs after chronic and short-termed exposure durations
por: Zarn, Jürg A., et al.
Publicado: (2017)

Advancing a Framework for Regulatory Use of Real-World Evidence: When Real Is Reliable
por: Dreyer, Nancy A.
Publicado: (2018)

Indian regulatory update April–October 2018
por: Bhave, Amita, et al.
Publicado: (2019)

A framework for the use of single-chemical transcriptomics data in predicting the hazards associated with complex mixtures of polycyclic aromatic hydrocarbons
por: Labib, Sarah, et al.
Publicado: (2016)

Recommended approaches in the application of toxicogenomics to derive points of departure for chemical risk assessment
por: Farmahin, Reza, et al.
Publicado: (2016)

Screening of repeated dose toxicity data in safety evaluation reports of cosmetic ingredients issued by the Scientific Committee on Consumer Safety between 2009 and 2019
por: Gustafson, Emma, et al.
Publicado: (2020)

Indian regulatory update during the COVID-19 pandemic
por: Bhave, Amita Chandan
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_c1mkq5cqqefo0fv4gmp4i6cmn5